Intellia Therapeutics

YTD

ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

845.74M

Market cap845.74M

Price-Earnings ratio

-1.56

Price-Earnings ratio-1.56

Dividend yield

—

Dividend yield—

Average volume

2.80M

Average volume2.80M

High today

$8.34

High today$8.34

Low today

$7.82

Low today$7.82

Open price

$8.04

Open price$8.04

Volume

730.55K

Volume730.55K

52 Week high

$28.18

52 Week high$28.18

52 Week low

$5.90

52 Week low$5.90

NTLA News

Benzinga 4d

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms

On Friday, Cathie Wood-led Ark Invest made several significant trades. The most prominent among these involved the buying and selling of shares in Intellia Ther...

Analyst ratings

75%

of 28 ratings

Buy

75%

Hold

21.4%

Sell

3.6%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.